Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects.
Glyburide and other sulfonylureas consistently enhance receptor binding in cells from patients with non-insulin-dependent diabetes mellitus, whereas no effects and mixed effects have been demonstrated in cells from patients with insulin-dependent diabetes mellitus and in normal cells, respectively. These findings indicate that the experimental model may be critical in demonstrating sulfonylurea effects on receptor binding. Postbinding function studies have shown a definite enhancement of peripheral glucose metabolism by sulfonylurea drugs; such post-receptor changes have not clearly correlated with receptor binding alterations. Studies using mouse-cultured myocytes indicate that both glyburide and tolazamide have stimulatory effects on glucose uptake, whereas only glyburide caused an increase in receptor binding. The data suggest a major and widespread post-receptor function for the sulfonylurea drugs, particularly glyburide, possibly mediated through pathways similar but not identical to insulin pathways. The direct receptor effects, in contrast, are possibly more tissue-specific and/or disease-dependent. In non-insulin-dependent diabetes mellitus, these drugs exert clinical efficacy by acting through both mechanisms.[1]References
- Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects. Gavin, J.R. Am. J. Med. (1985) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg